Review
Open access
Sep 2026
BEYOND DOPAMINE BLOCKADE: MUSCARINIC RECEPTOR AGONISM AS A NOVEL THERAPEUTIC STRATEGY IN SCHIZOPHRENIA - A LITERATURE REVIEW OF XANOMELINE-TROSPIUM
Xanomeline–trospium represents a promising alternative for schizophrenia treatment, particularly for patients intolerant to conventional antipsychotics or those with metabolic comorbidities.
Przemysław Dominik Drabik, Diana Morawska, A. Pelczar et al.
· International Journal of Inn... · 0 citations